1
|
Honda T, Kabashima K, Kunisawa J. Exploring the roles of prostanoids, leukotriens, and dietary fatty acids in cutaneous inflammatory diseases: Insights from pharmacological and genetic approaches. Immunol Rev 2023; 317:95-112. [PMID: 36815685 DOI: 10.1111/imr.13193] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
Prostanoids and leukotrienes (LTs) are representative of ω6 fatty acid-derived metabolites that exert their actions through specific receptors on the cell surface. These lipid mediators, being unstable in vivo, act locally at their production sites; thus, their physiological functions remain unclear. However, recent pharmacological and genetic approaches using experimental murine models have provided significant insights into the roles of these lipid mediators in various pathophysiological conditions, including cutaneous inflammatory diseases. These lipid mediators act not only through signaling by themselves but also by potentiating the signaling of other chemical mediators, such as cytokines and chemokines. For instance, prostaglandin E2 -EP4 and LTB4 -BLT1 signaling on cutaneous dendritic cells substantially facilitate their chemokine-induced migration ability into the skin and play critical roles in the priming and/or activation of antigen-specific effector T cells in the skin. In addition to these ω6 fatty acid-derived metabolites, various ω3 fatty acid-derived metabolites regulate skin immune cell functions, and some exert potent anti-inflammatory functions. Lipid mediators act as modulators of cutaneous immune responses, and manipulating the signaling from lipid mediators has the potential as a novel therapeutic approach for human skin diseases.
Collapse
Affiliation(s)
- Tetsuya Honda
- Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Kenji Kabashima
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
- Singapore Immunology Network (SIgN), Agency for Science, Technology, and Research (A*STAR), Biopolis, Singapore, Singapore
- 5. A*Star Skin Research Labs (A*SRL), Agency for Science, Technology, and Research (A*STAR), Biopolis, Singapore, Singapore
| | - Jun Kunisawa
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, Collaborative Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
- International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- Graduate School of Medicine, Graduate School of Dentistry, Graduate School of Pharmaceutical Sciences, Graduate School of Science, Osaka University, Osaka, Japan
- Department of Microbiology and Immunology, Graduate School of Medicine, Kobe University, Kobe, Japan
- Research Organization for Nano and Life Innovation, Waseda University, Tokyo, Japan
- Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| |
Collapse
|
2
|
Lv H, Wang Y, Gao Z, Liu P, Qin D, Hua Q, Xu Y. Knowledge mapping of the links between the microbiota and allergic diseases: A bibliometric analysis (2002-2021). Front Immunol 2022; 13:1045795. [PMID: 36389800 PMCID: PMC9650552 DOI: 10.3389/fimmu.2022.1045795] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Accepted: 10/14/2022] [Indexed: 08/17/2023] Open
Abstract
Background In recent decades, dramatic changes in modern environmental exposures and lifestyles have resulted in a steep rise in the prevalence of allergic diseases such as asthma, allergic rhinitis, atopic dermatitis and food allergies. Evidence is mounting that the microbiota plays a crucial role in allergic disorder development and evolution. Therefore, a better understanding of allergic diseases within the context of the microbiota is urgently needed. This work aimed to comprehensively outline general characteristics, research hotspots, evolution routes, and emerging trends in this area. Methods Relevant publications from January 2002 to December 2021 were obtained from the Web of Science Core Collection on 5 August 2022. Bibliometric and visual analyses were performed using CiteSpace; VOSviewer; an online bibliometric platform; and Microsoft Excel 2019. Results In total, 2535 documents met the requirements. The annual number of publications has shown rapid growth in the last two decades. The USA, University of California System, and Isolauri E of the University of Turku were the most productive and influential country, institution, and author, respectively. The Journal of Allergy and Clinical Immunology was the most prolific and most cocited journal. High-frequency keywords included "gut microbiota", "asthma", "atopic dermatitis", "children", and "probiotics". Recent studies have focused on "atopic dermatitis", "skin", "asthma", and "probiotics", according to the cocitation analysis of references. Burst detection analysis of keywords showed that "community", "skin microbiome", "microbiome", "Staphylococcus aureus", and "chain fatty acid" were emerging research frontiers, which currently have ongoing bursts. Conclusion In the last 20 years, studies of the microbiota in allergic diseases have been flourishing, and the themes have been increasing in depth. These findings provide valuable references on the current research hotspots and gaps and development trends in the link between the microbiota and allergic diseases.
Collapse
Affiliation(s)
- Hao Lv
- Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China
| | - Yunfei Wang
- Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China
| | - Ziang Gao
- Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China
| | - Peiqiang Liu
- Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China
| | - Danxue Qin
- Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China
| | - Qingquan Hua
- Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China
- Research Institute of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China
| | - Yu Xu
- Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China
- Research Institute of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China
| |
Collapse
|
3
|
Nagatake T, Kishino S, Urano E, Murakami H, Kitamura N, Konishi K, Ohno H, Tiwari P, Morimoto S, Node E, Adachi J, Abe Y, Isoyama J, Sawane K, Honda T, Inoue A, Uwamizu A, Matsuzaka T, Miyamoto Y, Hirata SI, Saika A, Shibata Y, Hosomi K, Matsunaga A, Shimano H, Arita M, Aoki J, Oka M, Matsutani A, Tomonaga T, Kabashima K, Miyachi M, Yasutomi Y, Ogawa J, Kunisawa J. Intestinal microbe-dependent ω3 lipid metabolite αKetoA prevents inflammatory diseases in mice and cynomolgus macaques. Mucosal Immunol 2022; 15:289-300. [PMID: 35013573 PMCID: PMC8866125 DOI: 10.1038/s41385-021-00477-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2021] [Revised: 12/08/2021] [Accepted: 12/09/2021] [Indexed: 02/07/2023]
Abstract
Dietary ω3 fatty acids have important health benefits and exert their potent bioactivity through conversion to lipid mediators. Here, we demonstrate that microbiota play an essential role in the body's use of dietary lipids for the control of inflammatory diseases. We found that amounts of 10-hydroxy-cis-12-cis-15-octadecadienoic acid (αHYA) and 10-oxo-cis-12-cis-15-octadecadienoic acid (αKetoA) increased in the feces and serum of specific-pathogen-free, but not germ-free, mice when they were maintained on a linseed oil diet, which is high in α-linolenic acid. Intake of αKetoA, but not αHYA, exerted anti-inflammatory properties through a peroxisome proliferator-activated receptor (PPAR)γ-dependent pathway and ameliorated hapten-induced contact hypersensitivity by inhibiting the development of inducible skin-associated lymphoid tissue through suppression of chemokine secretion from macrophages and inhibition of NF-κB activation in mice and cynomolgus macaques. Administering αKetoA also improved diabetic glucose intolerance by inhibiting adipose tissue inflammation and fibrosis through decreased macrophage infiltration in adipose tissues and altering macrophage M1/M2 polarization in mice fed a high-fat diet. These results collectively indicate that αKetoA is a novel postbiotic derived from α-linolenic acid, which controls macrophage-associated inflammatory diseases and may have potential for developing therapeutic drugs as well as probiotic food products.
Collapse
Affiliation(s)
- Takahiro Nagatake
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan
| | - Shigenobu Kishino
- grid.258799.80000 0004 0372 2033Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa-oiwakecho, Sakyo-ku, Kyoto, 606-8502 Japan
| | - Emiko Urano
- grid.482562.fLaboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, NIBIOHN, 1-1 Hachimandai, Tsukuba, Ibaraki, 305-0843 Japan
| | - Haruka Murakami
- grid.482562.fDepartment of Physical Activity Research, NIBIOHN, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8636 Japan
| | - Nahoko Kitamura
- grid.258799.80000 0004 0372 2033Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa-oiwakecho, Sakyo-ku, Kyoto, 606-8502 Japan
| | - Kana Konishi
- grid.482562.fDepartment of Physical Activity Research, NIBIOHN, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8636 Japan
| | - Harumi Ohno
- grid.482562.fDepartment of Physical Activity Research, NIBIOHN, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8636 Japan
| | - Prabha Tiwari
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan
| | - Sakiko Morimoto
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan
| | - Eri Node
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan
| | - Jun Adachi
- Laboratory of Proteome Research and Laboratory of Proteomics for Drug Discovery, NIBIOHN, 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan
| | - Yuichi Abe
- Laboratory of Proteome Research and Laboratory of Proteomics for Drug Discovery, NIBIOHN, 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan ,grid.410800.d0000 0001 0722 8444Division of Molecular Diagnostics, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681 Japan
| | - Junko Isoyama
- Laboratory of Proteome Research and Laboratory of Proteomics for Drug Discovery, NIBIOHN, 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan
| | - Kento Sawane
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan ,grid.136593.b0000 0004 0373 3971Graduate School of Pharmaceutical Sciences, Osaka University, 1-1 Yamadaoka, Suita, Osaka, 565-0871 Japan
| | - Tetsuya Honda
- grid.258799.80000 0004 0372 2033Department of Dermatology, Kyoto University Graduate School of Medicine, 54 Shogoin Kawara-cho, Kyoto, 606-8507 Japan ,grid.505613.40000 0000 8937 6696Department of Dermatology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192 Japan
| | - Asuka Inoue
- grid.69566.3a0000 0001 2248 6943Department of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi 980-8578 Japan
| | - Akiharu Uwamizu
- grid.69566.3a0000 0001 2248 6943Department of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi 980-8578 Japan ,grid.26999.3d0000 0001 2151 536XGraduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033 Japan
| | - Takashi Matsuzaka
- grid.20515.330000 0001 2369 4728Department of Endocrinology and Metabolism, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575 Japan ,grid.20515.330000 0001 2369 4728Transborder Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575 Japan
| | - Yoichi Miyamoto
- Laboratory of Nuclear Transport Dynamics, NIBIOHN, 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan
| | - So-ichiro Hirata
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan ,grid.31432.370000 0001 1092 3077Department of Microbiology and Immunology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017 Japan
| | - Azusa Saika
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan ,grid.136593.b0000 0004 0373 3971Graduate School of Pharmaceutical Sciences, Osaka University, 1-1 Yamadaoka, Suita, Osaka, 565-0871 Japan
| | - Yuki Shibata
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan ,grid.136593.b0000 0004 0373 3971Graduate School of Pharmaceutical Sciences, Osaka University, 1-1 Yamadaoka, Suita, Osaka, 565-0871 Japan
| | - Koji Hosomi
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan
| | - Ayu Matsunaga
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan ,grid.412904.a0000 0004 0606 9818Faculty of Agriculture, Takasaki University of Health and Welfare, 54 Nakaoruimachi, Takasaki, Gumma 370-0033 Japan
| | - Hitoshi Shimano
- grid.20515.330000 0001 2369 4728Department of Endocrinology and Metabolism, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575 Japan
| | - Makoto Arita
- grid.26091.3c0000 0004 1936 9959Division of Physiological Chemistry and Metabolism, Keio University Faculty of Pharmacy, 1-5-30 Shibakouen, Minato-ku, Tokyo, 105-8512 Japan ,grid.509459.40000 0004 0472 0267Laboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045 Japan ,grid.268441.d0000 0001 1033 6139Cellular and Molecular Epigenetics Laboratory, Graduate School of Medical Life Science, Yokohama City University, 1-7-29 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045 Japan
| | - Junken Aoki
- grid.69566.3a0000 0001 2248 6943Department of Molecular and Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi 980-8578 Japan ,grid.26999.3d0000 0001 2151 536XGraduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033 Japan
| | - Masahiro Oka
- Laboratory of Nuclear Transport Dynamics, NIBIOHN, 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan
| | - Akira Matsutani
- Department of Internal Medicine, Shunan City Shin-nanyo Hospital, 2-3-15 Miyanomae, Shunan, Yamaguchi, 746-0017 Japan
| | - Takeshi Tomonaga
- Laboratory of Proteome Research and Laboratory of Proteomics for Drug Discovery, NIBIOHN, 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan
| | - Kenji Kabashima
- grid.258799.80000 0004 0372 2033Department of Dermatology, Kyoto University Graduate School of Medicine, 54 Shogoin Kawara-cho, Kyoto, 606-8507 Japan
| | - Motohiko Miyachi
- grid.482562.fDepartment of Physical Activity Research, NIBIOHN, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8636 Japan
| | - Yasuhiro Yasutomi
- grid.482562.fLaboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, NIBIOHN, 1-1 Hachimandai, Tsukuba, Ibaraki, 305-0843 Japan
| | - Jun Ogawa
- grid.258799.80000 0004 0372 2033Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa-oiwakecho, Sakyo-ku, Kyoto, 606-8502 Japan
| | - Jun Kunisawa
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki, Osaka, 567-0085 Japan ,grid.136593.b0000 0004 0373 3971Graduate School of Pharmaceutical Sciences, Osaka University, 1-1 Yamadaoka, Suita, Osaka, 565-0871 Japan ,grid.31432.370000 0001 1092 3077Department of Microbiology and Immunology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017 Japan ,grid.26999.3d0000 0001 2151 536XInternational Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639 Japan ,grid.136593.b0000 0004 0373 3971Graduate School of Medicine, Graduate School of Dentistry, Osaka University, 1-1 Yamadaoka, Suita, Osaka, 565-0871 Japan ,grid.5290.e0000 0004 1936 9975Research Organization for Nano and Life Innovation, Waseda University, Tokyo, 162-0041 Japan
| |
Collapse
|
4
|
Wu CY, Okuda T, Ando A, Hatano A, Kikukawa H, Ogawa J. Isolation and characterization of the ω3-docosapentaenoic acid-producing microorganism Aurantiochytrium sp. T7. J Biosci Bioeng 2021; 133:229-234. [PMID: 34893429 DOI: 10.1016/j.jbiosc.2021.10.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Revised: 10/11/2021] [Accepted: 10/31/2021] [Indexed: 11/29/2022]
Abstract
ω3-Docosapentaenoic acid (ω3-DPA), an ω3-polyunsaturated fatty acid (ω3-PUFA), is expected to have beneficial physiological functions to humans; however, because of its rarity in nature, it has not been fully analyzed. We isolated an ω3-DPA producing microorganism strain T7 from brackish areas in Japan. Although most oleaginous microorganisms rarely accumulate ω3-DPA (<5% of total lipid), strain T7 accumulated ω3-DPA with more than 20% of total fatty acids. The strain T7 was identified as a related species of Aurantiochytrium. In Aurantiochytrium sp. T7, ω3-DPA production reached 164 mg/L culture broth, and the ω3-DPA content reached 23.5% of the total fatty acids when cultivated in a medium containing 2% glucose as the carbon source and 1% yeast extract as the nitrogen source, with a salinity equivalent to 50% of that of seawater and a pH in the acidic range (pH < 5.5). Aurantiochytrium sp. T7 is a promising producer of high-purity ω3-DPA containing-lipid for the functional analysis of ω3-DPA whose physiological function has hardly been elucidated, and a useful strain for investigating the novel metabolic pathway of fatty acids.
Collapse
Affiliation(s)
- Chang-Yu Wu
- Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa-oiwakecho, Sakyo-ku, Kyoto 606-8052, Japan
| | - Tomoyo Okuda
- Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa-oiwakecho, Sakyo-ku, Kyoto 606-8052, Japan
| | - Akinori Ando
- Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa-oiwakecho, Sakyo-ku, Kyoto 606-8052, Japan; Research Unit for Physiological Chemistry, Kyoto University, Kitashirakawa-oiwakecho, Sakyo-ku, Kyoto 606-8052, Japan
| | - Ayami Hatano
- Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa-oiwakecho, Sakyo-ku, Kyoto 606-8052, Japan
| | - Hiroshi Kikukawa
- Department of Environmental and Life Sciences, School of Food and Nutritional Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan
| | - Jun Ogawa
- Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa-oiwakecho, Sakyo-ku, Kyoto 606-8052, Japan; Research Unit for Physiological Chemistry, Kyoto University, Kitashirakawa-oiwakecho, Sakyo-ku, Kyoto 606-8052, Japan.
| |
Collapse
|
5
|
12-Hydroxyeicosapentaenoic acid inhibits foam cell formation and ameliorates high-fat diet-induced pathology of atherosclerosis in mice. Sci Rep 2021; 11:10426. [PMID: 34001916 PMCID: PMC8129127 DOI: 10.1038/s41598-021-89707-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Accepted: 04/26/2021] [Indexed: 02/02/2023] Open
Abstract
Atherosclerosis is a chronic inflammatory disease associated with macrophage aggregate and transformation into foam cells. In this study, we sought to investigate the impact of dietary intake of ω3 fatty acid on the development of atherosclerosis, and demonstrate the mechanism of action by identifying anti-inflammatory lipid metabolite. Mice were exposed to a high-fat diet (HFD) supplemented with either conventional soybean oil or α-linolenic acid-rich linseed oil. We found that as mice became obese they also showed increased pulsatility and resistive indexes in the common carotid artery. In sharp contrast, the addition of linseed oil to the HFD improved pulsatility and resistive indexes without affecting weight gain. Histological analysis revealed that dietary linseed oil inhibited foam cell formation in the aortic valve. Lipidomic analysis demonstrated a particularly marked increase in the eicosapentaenoic acid-derived metabolite 12-hydroxyeicosapentaenoic acid (12-HEPE) in the serum from mice fed with linseed oil. When we gave 12-HEPE to mice with HFD, the pulsatility and resistive indexes was improved. Indeed, 12-HEPE inhibited the foamy transformation of macrophages in a peroxisome proliferator-activated receptor (PPAR)γ-dependent manner. These results demonstrate that the 12-HEPE-PPARγ axis ameliorates the pathogenesis of atherosclerosis by inhibiting foam cell formation.
Collapse
|
6
|
Saika A, Kunisawa J. [Pharmacological Interaction between Diets and Commensal Bacteria for the Creation of Lipid Environment in the Control of Health and Diseases]. YAKUGAKU ZASSHI 2021; 141:681-688. [PMID: 33952752 DOI: 10.1248/yakushi.20-00243-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The intestine is exposed to a variety of exogenous materials that are harmful, harmless, or useful, such as pathogenic viruses and bacteria, intestinal bacteria, or food components. As such, the intestinal immune system is important for the regulation of immunological homeostasis and biological defense. Accumulating evidence indicates that gut environmental factors, such as dietary components and intestinal bacteria are critical for controlling intestinal immunity, and thereby, health and disease. Among the important dietary components are fatty acids, which are metabolized to lipid mediators that act as signaling molecules and regulate immune responses. In previous work, we identified lipid mediators derived from ω3 fatty acids, such as 17,18-epoxyeicosatetraenoic acid, 15-hydroxyeicosapentaenoic acid, and 14-hydroxydocosapentaenoic acid, which show potent anti-allergic and anti-inflammatory activities. In addition, we revealed that lipid mediators play key roles in the enhancement of intestinal Immunoglobulin A responses, which provide the first line of defense against viral and bacterial infectious diseases. Here, we review the anti-allergic, anti-inflammatory, and host-protective effects of lipid mediators mainly derived from dietary lipids.
Collapse
Affiliation(s)
- Azusa Saika
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition.,Graduate School of Pharmaceutical Sciences, Osaka University
| | - Jun Kunisawa
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition.,Graduate School of Pharmaceutical Sciences, Osaka University.,International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo.,Graduate School of Medicine, Osaka University.,Graduate School of Dentistry, Osaka University.,Graduate School of Medicine, Kobe University.,School of Dentistry, Hiroshima University.,Research Organization for Nano & Life Innovation, Waseda University
| |
Collapse
|
7
|
Saika A, Nagatake T, Hirata SI, Sawane K, Adachi J, Abe Y, Isoyama J, Morimoto S, Node E, Tiwari P, Hosomi K, Matsunaga A, Honda T, Tomonaga T, Arita M, Kabashima K, Kunisawa J. ω3 fatty acid metabolite, 12-hydroxyeicosapentaenoic acid, alleviates contact hypersensitivity by downregulation of CXCL1 and CXCL2 gene expression in keratinocytes via retinoid X receptor α. FASEB J 2021; 35:e21354. [PMID: 33749892 DOI: 10.1096/fj.202001687r] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Revised: 12/14/2020] [Accepted: 12/23/2020] [Indexed: 11/11/2022]
Abstract
ω3 fatty acids show potent bioactivities via conversion into lipid mediators; therefore, metabolism of dietary lipids is a critical determinant in the properties of ω3 fatty acids in the control of allergic inflammatory diseases. However, metabolic progression of ω3 fatty acids in the skin and their roles in the regulation of skin inflammation remains to be clarified. In this study, we found that 12-hydroxyeicosapentaenoic acid (12-HEPE), which is a 12-lipoxygenase metabolite of eicosapentaenoic acid, was the prominent metabolite accumulated in the skin of mice fed ω3 fatty acid-rich linseed oil. Consistently, the gene expression levels of Alox12 and Alox12b, which encode proteins involved in the generation of 12-HEPE, were much higher in the skin than in the other tissues (eg, gut). We also found that the topical application of 12-HEPE inhibited the inflammation associated with contact hypersensitivity by inhibiting neutrophil infiltration into the skin. In human keratinocytes in vitro, 12-HEPE inhibited the expression of two genes encoding neutrophil chemoattractants, CXCL1 and CXCL2, via retinoid X receptor α. Together, the present results demonstrate that the metabolic progression of dietary ω3 fatty acids differs in different organs, and identify 12-HEPE as the dominant ω3 fatty acid metabolite in the skin.
Collapse
Affiliation(s)
- Azusa Saika
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.,Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
| | - Takahiro Nagatake
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
| | - So-Ichiro Hirata
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
| | - Kento Sawane
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.,Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.,Nippon Flour Mills Co., Ltd, Innovation Center, Atsugi, Japan
| | - Jun Adachi
- Laboratory of Proteome Research and Laboratory of Proteomics for Drug Discovery, NIBIOHN, Osaka, Japan
| | - Yuichi Abe
- Laboratory of Proteome Research and Laboratory of Proteomics for Drug Discovery, NIBIOHN, Osaka, Japan.,Division of Molecular Diagnosis, Aichi Cancer Center Research Institute, Nagoya, Japan
| | - Junko Isoyama
- Laboratory of Proteome Research and Laboratory of Proteomics for Drug Discovery, NIBIOHN, Osaka, Japan
| | - Sakiko Morimoto
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
| | - Eri Node
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
| | - Prabha Tiwari
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
| | - Koji Hosomi
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
| | - Ayu Matsunaga
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.,Department of Food and Life Science, School of Life and Environmental Science, Azabu University, Sagamihara, Japan
| | - Tetsuya Honda
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.,Department of Dermatology, Hamamatsu University School of Medicine, Shizuoka, Japan
| | - Takeshi Tomonaga
- Laboratory of Proteome Research and Laboratory of Proteomics for Drug Discovery, NIBIOHN, Osaka, Japan
| | - Makoto Arita
- Division of Physiological Chemistry and Metabolism, Faculty of Pharmacy, Keio University, Tokyo, Japan.,Laboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.,Cellular and Molecular Epigenetics Laboratory, Graduate School of Medical Life Science, Yokohama City University, Yokohama, Japan
| | - Kenji Kabashima
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Jun Kunisawa
- Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.,Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.,Department of Microbiology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.,International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.,Graduate School of Medicine, Graduate School of Dentistry, Osaka University, Suita, Japan
| |
Collapse
|
8
|
Ghasemi Fard S, Cameron-Smith D, Sinclair AJ. n - 3 Docosapentaenoic acid: the iceberg n - 3 fatty acid. Curr Opin Clin Nutr Metab Care 2021; 24:134-138. [PMID: 33315722 DOI: 10.1097/mco.0000000000000722] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
PURPOSE OF REVIEW Docosapentaenoic acid (DPA) is a minor omega-3 fatty acid (FA) which has been frequently overlooked in lipid research. This review examines the biochemical and physiological outcomes of human trials which have used pure preparations of DPA (n - 3 DPA) and also recent developments in specialized proresolving lipid mediators (SPMs) derived from n - 3 DPA. RECENT FINDINGS There have been only been two human studies and eleven animal studies with pure n - 3 DPA. The doses of n - 3 DPA used in the human trials have been 1-2 g/day. n - 3 DPA abundance is increased in blood lipid fractions within 3-4 days of supplementation. n - 3 DPA has the potential for unique properties, with a greater similarity in biological functioning with docosahexaenoic acid (DHA), than eicosapentaenoic acid (EPA). Despite the typically low levels of n - 3 DPA in most tissue lipids relative to EPA and DHA, unique SPMs, such as resolvins, maresins and protectins of the n - 3 DPA type, are involved in resolution of inflammation and regulating immune function. SUMMARY We suggest that measurement of blood levels of n - 3 DPA gives no indication of its broad biological roles, but that the true functionality of this enigmatic n - 3 polyunsaturated fatty acid (PUFA) remains obscure until more is known about the properties of the unique DPA-derived SPMs.
Collapse
Affiliation(s)
- Samaneh Ghasemi Fard
- School of Life and Environmental Sciences, Deakin University, Melbourne, Victoria, Australia
| | - David Cameron-Smith
- Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (A∗STAR), Brenner Centre for Molecular Medicine, Singapore, Singapore
| | - Andrew J Sinclair
- Department of Nutrition, Dietetics and Food, Monash University
- Faculty of Health, Deakin University, Melbourne, Victoria, Australia
| |
Collapse
|
9
|
Hirata S, Nagatake T, Sawane K, Hosomi K, Honda T, Ono S, Shibuya N, Saito E, Adachi J, Abe Y, Isoyama J, Suzuki H, Matsunaga A, Tomonaga T, Kiyono H, Kabashima K, Arita M, Kunisawa J. Maternal ω3 docosapentaenoic acid inhibits infant allergic dermatitis through TRAIL-expressing plasmacytoid dendritic cells in mice. Allergy 2020; 75:1939-1955. [PMID: 32027039 PMCID: PMC7496639 DOI: 10.1111/all.14217] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Revised: 12/26/2019] [Accepted: 01/09/2020] [Indexed: 12/14/2022]
Abstract
Background Maternal dietary exposures are considered to influence the development of infant allergies through changes in the composition of breast milk. Cohort studies have shown that ω3 polyunsaturated fatty acids (PUFAs) in breast milk may have a beneficial effect on the preventing of allergies in infants; however, the underlying mechanisms remain to be investigated. We investigated how the maternal intake of dietary ω3 PUFAs affects fatty acid profiles in the breast milk and their pups and reduced the incidence of allergic diseases in the pups. Methods Contact hypersensitivity (CHS) induced by 2,4‐dinitrofluorobenzene (DNFB) and fluorescein isothiocyanate was applied to the skin in pups reared by mother maintained with diets mainly containing ω3 or ω6 PUFAs. Skin inflammation, immune cell populations, and expression levels of immunomodulatory molecules in pups and/or human cell line were investigated by using flow cytometric, immunohistologic, and quantitative RT‐PCR analyses. ω3 PUFA metabolites in breast milk and infant's serum were evaluated by lipidomics analysis using LC‐MS/MS. Results We show that maternal intake of linseed oil, containing abundant ω3 α‐linolenic acid, resulted in the increased levels of ω3 docosapentaenoic acid (DPA) and its 14‐lipoxygenation products in the breast milk of mouse dams; these metabolites increased the expression of TNF‐related apoptosis‐inducing ligand (TRAIL) on plasmacytoid dendritic cells (pDCs) in their pups and thus inhibited infant CHS. Indeed, the administration of DPA‐derived 14‐lipoxygenation products to mouse pups ameliorated their DNFB CHS. Conclusion These findings suggest that an inhibitory mechanism in infant skin allergy is induced through maternal metabolism of dietary ω3 PUFAs in mice.
Collapse
Affiliation(s)
- So‐ichiro Hirata
- Laboratory of Vaccine Materials Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) Ibaraki‐city Japan
- Department of Microbiology and Immunology Kobe University Graduate School of Medicine Kobe‐city Japan
| | - Takahiro Nagatake
- Laboratory of Vaccine Materials Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) Ibaraki‐city Japan
| | - Kento Sawane
- Laboratory of Vaccine Materials Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) Ibaraki‐city Japan
- Nippon Flour Mills Co., Ltd., Innovation Center Atsugi‐city Japan
- Graduate School of Pharmaceutical Sciences Osaka University Suita‐city Japan
| | - Koji Hosomi
- Laboratory of Vaccine Materials Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) Ibaraki‐city Japan
| | - Tetsuya Honda
- Department of Dermatology Kyoto University Graduate School of Medicine Kyoto‐city Japan
| | - Sachiko Ono
- Department of Dermatology Kyoto University Graduate School of Medicine Kyoto‐city Japan
| | - Noriko Shibuya
- Department of Pediatrics Maternal & Child Health Center, Aiiku Clinic Tokyo Japan
| | - Emiko Saito
- Department of Human Nutrition Tokyo Kasei Gakuin University Tokyo Japan
| | - Jun Adachi
- Laboratory of Proteome Research National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) Ibaraki‐city Japan
| | - Yuichi Abe
- Laboratory of Proteome Research National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) Ibaraki‐city Japan
| | - Junko Isoyama
- Laboratory of Proteome Research National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) Ibaraki‐city Japan
| | - Hidehiko Suzuki
- Laboratory of Vaccine Materials Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) Ibaraki‐city Japan
| | - Ayu Matsunaga
- Laboratory of Vaccine Materials Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) Ibaraki‐city Japan
| | - Takeshi Tomonaga
- Laboratory of Proteome Research National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) Ibaraki‐city Japan
| | - Hiroshi Kiyono
- International Research and Development Center for Mucosal Vaccines The Institute of Medical ScienceThe University of Tokyo Tokyo Japan
- Division of Gastroenterology Department of Medicine University of California San Diego (UCSD) San Diego CA USA
- Chiba University (CU)‐UCSD Center for Mucosal Immunology, Allergy and Vaccines (cMAV) UCSD San Diego CA USA
- Department of Immunology Graduate School of Medicine Chiba University Chiba‐city Japan
| | - Kenji Kabashima
- Department of Dermatology Kyoto University Graduate School of Medicine Kyoto‐city Japan
| | - Makoto Arita
- Laboratory for Metabolomics RIKEN Center for Integrative Medical Sciences Yokohama‐city Japan
- Division of Physiological Chemistry and Metabolism Graduate School of Pharmaceutical Sciences Keio University Tokyo Japan
- Graduate School of Medical Life Science Yokohama City University Yokohama‐city Japan
| | - Jun Kunisawa
- Laboratory of Vaccine Materials Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) Ibaraki‐city Japan
- Department of Microbiology and Immunology Kobe University Graduate School of Medicine Kobe‐city Japan
- Graduate School of Pharmaceutical Sciences Osaka University Suita‐city Japan
- International Research and Development Center for Mucosal Vaccines The Institute of Medical ScienceThe University of Tokyo Tokyo Japan
- Graduate School of Medicine and Graduate School of Dentistry Osaka University Suita‐city Japan
| |
Collapse
|